Abstracts Archive - Page 910 of 2425 - ACR Meeting Abstracts

Abstract Number: 2275 • 2019 ACR/ARP Annual Meeting
Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis
Ravyn Njagu¹, Amanda Eudy ², Stephen Balevic ³, Michelle Petri ⁴, Dafna Gladman ⁵, Murray Urowitz ⁶ and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University, Hillsborough, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individual cohort studies have found that Black and Hispanic women have worse pregnancy outcomes compared to their white counterparts. Additionally, this population of women…
Abstract Number: 2276 • 2019 ACR/ARP Annual Meeting
Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach
Ravyn Njagu¹, Amanda Eudy ², Amanda Snyderman ¹, Lisa Criscione-Schreiber ² and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: While centers have worked to optimize lupus pregnancy outcomes, additional efforts are required to have a broader impact on lupus pregnancy outcomes. The goal…
Abstract Number: 2277 • 2019 ACR/ARP Annual Meeting
Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists
Tierney Wolgemuth ¹, Mehret Birru Talabi ¹, Alaina Chodoff ², Sonya Borrero ³ and Mehret Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Women with rheumatic diseases may be at greater risk for adverse maternal, perinatal, and pregnancy outcomes. The American College of Rheumatology recommends that female…
Abstract Number: 2278 • 2019 ACR/ARP Annual Meeting
Perspectives About Contraception Among Reproductive-Aged Women with Rheumatic Diseases
Olivia Stransky ¹, Tierney Wolgemuth ¹, Alaina Chodoff ² and Mehret Birru Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh
Background/Purpose: Prior work suggests that women with rheumatic diseases are rarely prescribed contraception. However, in addition to preventing undesired pregnancy, contraception may help these women…
Abstract Number: 2279 • 2019 ACR/ARP Annual Meeting
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Isabell Haase¹, Susanna Spaethling-Mestekemper ², Ralph Brinks ¹, Matthias Schneider ³ and Rebecca Fischer-Betz ³, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumapraxis, Munich, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Women with active Rheumatoid Arthritis (RA) are more prone to relapses and complications during pregnancy. The potential risks of disease activation and treatment during…
Abstract Number: 2280 • 2019 ACR/ARP Annual Meeting
Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention
Katherine Pryor¹, Bill Albert ², Susan Ritter ³, Laura Tarter ³, Jonathan Coblyn ³, Bonnie Bermas ⁴, Caryn Dutton ³, Lydia Pace ³, Elizabeth Janiak ³ and Candace Feldman ⁵, ¹Brigham and Women's Hospital, Brookline, ²Power to Decide, Washington, DC, ³Brigham and Women's Hospital, Boston, ⁴UT Southwestern, Dallas, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Reproductive health intention screening is critical in women with systemic rheumatic diseases, as both disease activity and medication use can impact pregnancy outcomes. However,…
Abstract Number: 2281 • 2019 ACR/ARP Annual Meeting
The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years
Jon Golenbiewski¹, Kalen Young ², Cristina Burroughs ³, Joyce Kullman ², Peter Merkel ⁴ and Megan Clowse ⁵, ¹Duke University Medical Center, Durham, NC, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University, Durham
Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage…
Abstract Number: 2282 • 2019 ACR/ARP Annual Meeting
Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population
Kimberly Showalter¹, Melanie Smith ², Jonathan Cheah ², Nilasha Ghosh ², Elena Gkrouzman ², Sarah Lieber ², Sebastian Sattui ², Noa Schwartz ², Monica Schwartzman ², Jessica Berman ², Lisa Sammaritano ² and Anne Bass ³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Women of reproductive age with rheumatic diseases are often prescribed teratogenic medications; thus, reproductive counseling is important. A prior study demonstrated improvement in counseling…
Abstract Number: 2283 • 2019 ACR/ARP Annual Meeting
Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients
Brooke Mills¹ and Bonnie Bermas ¹, ¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: While the benefits of breastfeeding for both the mother and her infant are well established, available resources regarding medication compatibility with lactation are limited. …
Abstract Number: 2284 • 2019 ACR/ARP Annual Meeting
The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development
Hiromi Shimada¹, Risa Wakiya ², Mai Mahmoud Fahmy Mansour ², Shusaku Nakashima ², Mikiya Kato ², Taichi Miyagi ², Tomohiro Kameda ² and Hiroaki Dobashi ¹, ¹Kagawa University, Kagawa, Japan, ²Kagawa University, Kagawa
Background/Purpose: Recently, the progression of treatment strategy enabled many systemic lupus erythematosus (SLE) women to become mothers. On the other hand, some reports have revealed…
Abstract Number: 2285 • 2019 ACR/ARP Annual Meeting
Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers
Ashley Blaske¹, Amanda Eudy ², Katie Kirchoff ³, Jim Oates ⁴, Megan Clowse ² and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke University, Durham, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC
Background/Purpose: Prospective cohort studies of pregnancies managed by experts demonstrate that up to 30% of systemic lupus erythematosus (SLE) pregnancies result in preterm birth. We…
Abstract Number: 2286 • 2019 ACR/ARP Annual Meeting
Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?
Jutta Richter¹, Christina Bungartz ², Anja Weiß ³, Rebecca Fischer-Betz ⁴, Angela Zink ⁵, Matthias Schneider ¹ and Anja Strangfeld ³, ¹Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ²German Rheumatism Research Center (DRFZ), Berlin, Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: The German pregnancy register Rhekiss is designed as a nationwide, web-based longitudinal observational register established in 2015. The register follows women with inflammatory rheumatic…
Abstract Number: 2287 • 2019 ACR/ARP Annual Meeting
Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion
Hindi Stohl ¹, Ning Yu ² and William Stohl², ¹Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Immunologic, angiogenic, and anti-angiogenic factors have been associated with spontaneous abortion (SAB), yet early identification of those pregnant women who ultimately undergo SAB remains…
Abstract Number: 2288 • 2019 ACR/ARP Annual Meeting
Pregnancy Outcomes in Women Exposed to Golimumab
Suzan Esslinger¹, Susan Gabriel ², Marijo Otero-Lobato ³, Michael Clark ⁴, Pamela Sheridan ⁴ and Anja Geldhof ⁵, ¹Janssen Biologics BV, Leiden, Netherlands, ²Janssen Rearch & Development, LLC, Horsham, PA, ³Janssen Biologics BV, Leiden, Zuid-Holland, Netherlands, ⁴Janssen Research & Development, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Leiden, Netherlands
Background/Purpose: Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic…
Abstract Number: 2289 • 2019 ACR/ARP Annual Meeting
Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells
Zejun Zhou ¹, Gary Gilkeson ², Diane Kamen ³, Jim Oates ⁴ and Wei Jiang⁴, ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ⁴Medical University of South Carolina, Charleston
Background/Purpose: Progesterone plays a protective role in preventing inflammation and preterm delivery during pregnancy. However, the mechanism involved is unknown. Microbial product translocation from a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].